Opportunity Radar

← Back to search

Grant

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
CA
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
PAR-25-297
Posted
Dec 4, 2024
Response due
Nov 5, 2027
Archive date
Dec 11, 2027
CFDA / Assistance listing
93.866
Award ceiling
$1,500,000
Contact
grantsinfo@nih.gov
Source
Grants.gov

Description

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Similar open opportunities